How effective is AHCC in clearing high-risk HPV infections. What are the implications of the phase II trial results for HPV management. How does AHCC modulate host immunity against persistent HPV.

Understanding Persistent HPV Infections and Their Risks

Human Papillomavirus (HPV) infections are a significant health concern, particularly when they persist for extended periods. A persistent HPV infection is defined as one that lasts for more than two years. The longer an HPV infection remains active, the higher the risk of abnormal cell formation that could lead to cancer.

While most individuals with healthy immune systems can clear HPV infections naturally within two years, approximately 10% of people experience persistent infections. These persistent infections, especially those involving high-risk HPV strains, pose the greatest cancer risk.

Factors Contributing to Persistent HPV Infections

• Compromised immune system
• Poor diet
• Insufficient sleep
• High stress levels
• Advanced age

Currently, there is no systemic treatment available for persistent HPV infections. Existing treatment modalities focus on early detection through vaginal PAP smears, followed by localized treatments such as cryotherapy, surgical excision, loop electrosurgical excisional procedure (LEEP), or cold knife conization. While these treatments have a high response rate of 80%, patients often experience recurrent lesions.

The Promise of AHCC in Managing Persistent HPV Infections

AHCC (Active Hexose Correlated Compound) is emerging as a potential game-changer in the management of persistent HPV infections. But what exactly is AHCC?

AHCC is a proprietary, standardized extract derived from cultured lentinula edodes mycelia. It has demonstrated unique immune-modulatory benefits in various animal and human studies. These benefits include enhanced antioxidant effects, anticancer activity, and modulation of the immune system to combat both viral and bacterial infections.

Pilot Studies: AHCC’s Initial Promise

Two pilot studies laid the groundwork for further investigation into AHCC’s potential against persistent HPV infections:

1. In the first study, 50% of women (4 out of 8) with persistent HPV infections cleared their infection within 3 to 6 months of starting a daily 3g dose of AHCC on an empty stomach.
2. The second study, using a lower 1g daily dose of AHCC, showed a similar response rate of 44% (4 out of 9 women) confirming clearance of high-risk HPV persistent infections after 7 months of supplementation.

These promising results paved the way for a more comprehensive phase II trial to evaluate AHCC’s efficacy in clearing persistent HPV infections.

Phase II Trial: AHCC’s Effectiveness Against Persistent HPV

The phase II randomized, double-blind, placebo-controlled study, conducted by Dr. Judith Smith and approved by the University of Texas Health Sciences Center Institutional Review Board, aimed to determine the efficacy, safety, and durability of AHCC supplementation in clearing high-risk HPV infections.

Study Design and Methodology

• 50 women over age 30 with persistent HPV infections (lasting more than two years) were studied for 12 months
• Participants were randomized into two groups:
  • AHCC group: 3g AHCC daily on an empty stomach for 6 months, followed by placebo for 6 months
  • Control group: Placebo for 12 months
• Evaluations were conducted every 3 months, including:
  • HPV-DNA and HPV-RNA testing
  • Blood sample analysis for immune markers (interferon-alpha, interferon-beta, interferon-gamma, IgG1, T-lymphocytes, and natural killer cell levels)

Key Findings of the Phase II Trial

The results of the phase II trial were highly encouraging:

• 63.6% (14 out of 22) of the women who completed the AHCC supplementation protocol cleared their HPV infection
• Overall, AHCC supplementation showed a 58% effectiveness rate in clearing persistent HPV infections
• The study demonstrated the safety and tolerability of AHCC supplementation

These findings represent a significant breakthrough in the management of persistent HPV infections, offering hope to those at risk of developing HPV-related cancers.

Implications of AHCC Supplementation for HPV Management

The success of AHCC in clearing persistent HPV infections has far-reaching implications for HPV management and cancer prevention. How might this impact current medical practices and patient care?

Potential Shift in Treatment Paradigm

AHCC supplementation could potentially offer a systemic approach to treating persistent HPV infections, complementing or possibly reducing the need for localized treatments. This may lead to:

• Fewer invasive procedures
• Reduced risk of treatment-related complications
• Improved quality of life for patients
• Potential cost savings in healthcare

Enhanced Cancer Prevention Strategies

By effectively clearing persistent HPV infections, AHCC supplementation may significantly reduce the risk of HPV-related cancers. This could revolutionize cancer prevention strategies, particularly for high-risk individuals.

Mechanisms of Action: How AHCC Modulates Host Immunity

Understanding how AHCC works to enhance the immune system’s ability to clear HPV infections is crucial. What are the key mechanisms at play?

Immune System Modulation

AHCC has been shown to modulate various aspects of the immune system, including:

• Enhancing natural killer (NK) cell activity
• Increasing T-lymphocyte production
• Modulating cytokine production, including interferons
• Boosting overall immune system function

Antiviral Properties

AHCC’s antiviral properties may directly contribute to its effectiveness against HPV. This could involve:

• Inhibiting viral replication
• Enhancing the body’s ability to recognize and target infected cells
• Supporting the clearance of virus-infected cells

AHCC Supplementation: Dosage and Administration

Based on the phase II trial results, what is the recommended dosage and administration protocol for AHCC supplementation in managing persistent HPV infections?

Recommended Dosage

The study utilized a dosage of 3g of AHCC daily, taken on an empty stomach. This dosage was found to be both effective and well-tolerated by participants.

Duration of Supplementation

The trial protocol involved 6 months of AHCC supplementation. However, further research may be needed to determine the optimal duration for different patient populations.

Administration Guidelines

• Take AHCC on an empty stomach for optimal absorption
• Consistency in daily intake is crucial for effectiveness
• Regular monitoring and follow-up with healthcare providers is recommended

Safety Profile and Potential Side Effects of AHCC

While the phase II trial demonstrated the overall safety and tolerability of AHCC supplementation, it’s important to consider potential side effects and safety considerations. What should patients and healthcare providers be aware of?

Observed Side Effects

The study reported minimal side effects associated with AHCC supplementation. However, some patients may experience:

• Mild gastrointestinal discomfort
• Headaches
• Fatigue

Safety Considerations

While AHCC is generally considered safe, certain precautions should be taken:

• Consult with a healthcare provider before starting AHCC supplementation, especially for individuals with pre-existing medical conditions or those taking other medications
• Pregnant or breastfeeding women should seek medical advice before using AHCC
• Regular monitoring during supplementation is advised to ensure safety and efficacy

Future Directions: AHCC Research and Clinical Applications

The promising results of the phase II trial open up new avenues for research and potential clinical applications of AHCC in HPV management. What are the next steps in advancing this field of study?

Ongoing and Future Research

Several areas of research are likely to be pursued:

• Larger-scale clinical trials to further validate the efficacy of AHCC in clearing persistent HPV infections
• Studies on the long-term effects of AHCC supplementation
• Investigation of AHCC’s potential in preventing HPV-related cancers
• Research on combining AHCC with other treatment modalities for enhanced effectiveness

Potential Clinical Applications

The success of AHCC in clearing persistent HPV infections could lead to various clinical applications:

• Integration of AHCC supplementation into standard HPV management protocols
• Use of AHCC as a preventive measure for high-risk individuals
• Development of personalized treatment plans incorporating AHCC based on individual patient factors

As research progresses, AHCC may become an integral part of HPV management strategies, offering hope to millions of individuals affected by persistent HPV infections and at risk of HPV-related cancers.

The phase II trial results of AHCC supplementation in clearing persistent HPV infections mark a significant milestone in HPV management. With its demonstrated efficacy, safety profile, and potential to modulate host immunity, AHCC offers a promising approach to addressing a critical gap in current treatment options. As research continues and clinical applications expand, AHCC may play a pivotal role in reducing the burden of HPV-related diseases and improving patient outcomes worldwide.

AHCC Clears HPV Infections in Phase II Trial

People who have high-risk HPV fear getting cancer, but don’t know how to prevent it. The only advice doctors can provide is to support the immune system by eating well, sleeping well, and reducing stress. In support groups, survivors of HPV cancers express great fear that their HPV will lead to cancer yet again. So, for people who have high-risk HPV, any research on a supplement that supports the immune system’s ability to clear persistent HPV infections is profoundly significant. This new phase II study showing that AHCC is 58% effective at clearing persistent HPV infections provides hope for those of us who have high-risk HPV.

A persistent HPV infection is defined as one that lasts for more than two years, and the longer an HPV infection is active, the more likely it is that abnormal cancer cells will form. Although most people clear HPV infections naturally in 2 years if their immune system is strong, not everyone has a strong immune system. The immune system can be compromised by poor diet, insufficient sleep, stress, or just age. About 10% of people with HPV infections have persistent infections that last for more than 2 years. Since persistent high-risk HPV infections are the most likely to cause cancer, it is important to study these cases.

To date, there is no systemic treatment for persistent HPV infections. Current treatment modalities rely on early detection in vaginal PAP smears followed by treatments like cryotherapy, surgical excision, loop electrosurgical excisional procedure (LEEP), or cold knife conization. Although these treatments have a high response rate of 80%, patients will frequently have recurrent lesions. In addition, there is not yet an established medical protocol for screening and treating HPV infections in other parts of the body, like the anus. The Anchor Study, for example, has shown that screening for HPV and treating precancerous cells can lower the incidence of anal cancer. But this type of screening is in its infancy and only available in select locations. It would therefore be better to prevent these cell changes from happening in the first place. This phase II study of AHCC supplementation provides hope that persistent HPV infections can be prevented from progressing to cancer.

What Is AHCC?

The AHCC supplement is a proprietary, standardized extract of cultured lentinula edodes mycelia that has been shown to have unique immune modulatory benefits. Several animal and human studies have reported a variety of therapeutic effects, including enhanced antioxidant effects, anticancer activity, and modulation of the immune system to prevent the infectious processes of both viral and bacterial infections.  This new clinical trial suggests that AHCC can also help the immune system clear persistent HPV infections.

Pilot Studies of AHCC to Clear HPV Infections

AHCC originally showed promise in two pilot studies. In one study of women with persistent HPV infections, 4 out of the 8 women who remained in the study (50%) cleared their persistent HPV infection between 3 to 6 months after starting a 3g daily dose of AHCC on an empty stomach.  In a second pilot study, women were given 1g of AHCC a day on an empty stomach and showed a similar response rate: 4 out of the 9 women (44%) confirmed clearance of high-risk HPV persistent infections after 7 months of supplementation. These pilot studies provided the rationale to move forward with a phase II trial of AHCC to clear persistent HPV infections.

The New Phase II Study

Our medical advisory board member Judith Smith conducted this phase II randomized, double-blind, placebo-controlled study with a post unblinded study. This trial was reviewed and approved by the University of Texas Health Sciences Center Institutional Review Board. The objective of the study was to determine the efficacy, safety, and durability of AHCC supplementation for 6 months to support the host immune system to clear high-risk HPV infections.

Fifty women over age 30 with persistent HPV infections that had lasted more than two years were studied for 12 months. Patients were randomized into two groups: one group took AHCC 3g by mouth once daily on an empty stomach for six months followed by a placebo for the remaining 6 months. The control group was given a placebo. Every 3 months patients were evaluated with HPV-DNA and HPV-RNA testing and with a blood sample to evaluate a panel of immune markers including: interferon‐alpha(INN), interferon‐beta (IFNβ), interferon‐gamma (IFN), IgG1, T‐lymphocytes, and natural killer(NK) cell levels.

Of the 41 women who completed the study, fourteen (63.6%) of the 22 patients in the AHCC supplementation arm were HPV-RNA/HPV-DNA negative after six months, and 64.3% (9/14) achieved a durable response defined as also being HPV-RNA/HPV-DNA negative 12 months after the supplementation ended. In contrast, in the placebo arm of the study, only two (10.5%) of 19 patients were HPV negative at 12 months. An additional twelve patients completed the un-blinded study and 50% were HPV-RNA/HPV-DNA negative after six months of AHCC supplementation.

Combining all 34 participants that received AHCC supplementation gives an overall response rate of 58.8% that cleared HPV persistent infections.

Conclusions 

Results from this phase II study demonstrated that AHCC 3g once daily on an empty stomach was effective in supporting the host immune system’s elimination of persistent HPV infections and was well tolerated with no significant adverse side effects reported.

Directions for Further Research

 An additional finding of the study was that suppression of IFNβ to less than 20pg/mL correlated with an increase in T‐lymphocytes and IFN and durable clearance of HPV infections in women that received AHCC supplementation. This merits further evaluation as a clinical tool for monitoring patients with HPV infections. The duration of AHCC supplementation required beyond first negative result also needs more evaluation to optimize success for durable outcomes.

AHCC is Unique

It’s important to distinguish AHCC from other medicinal mushrooms. AHCC is the only medicinal mushroom that has been clinically demonstrated to help eradicate HPV. It is not interchangeable with other medicinal mushrooms because it has been specially developed and processed to maximize its immune-boosting capacity. AHCC is made by cell culturing a specific subspecies of mushroom identified by Japanese scientists several decades ago to have the greatest ability to increase natural killer cell activity. Its molecular weight has been reduced using a patented enzymatic process to improve its absorption and clinical efficacy. Every batch of AHCC is subjected to DNA pattern testing to confirm its identity (in other words, to ensure it is genuine AHCC). These innovations make AHCC unique among medicinal mushrooms.

AHCC is available from multiple nutritional supplement companies, but it is important to steer clear of fake products using different names yet claiming similar benefits. Only genuine AHCC® has been clinically tested and found to help clear HPV.

Click to read the full study

Here is a list of genuine AHCC products.

AHCC® is a registered trademark of the Amino Up Company

A Note for Anal Cancer Survivors

Because this study was conducted on women with vaginal HPV infections, we reached out to Dr. Romesser, a radiation oncologist specializing in anal cancer at Memorial Sloan Kettering, to ask about anal cancer survivors and AHCC. No side effects from AHCC were reported in women with vaginal HPV in the study described above; however, there is some anecdotal indication that there may be mild side effects for anal cancer survivors. Dr. Romesser has noticed that some anal cancer survivors experience side effects like anal itching when they start taking AHCC. Therefore, he recommends that anal cancer patients who have recently had treatment, wait to take AHCC until all the side effects from treatment have subsided.  It also seems that for some anal cancer survivors, the side effects from taking AHCC go away after a few weeks. It might be worthwhile to continue taking AHCC for a few weeks despite any side effects in case the side effects subside.

Can AHCC Cure HPV & How Much Should I Take?

The human papillomavirus, otherwise known as HPV, is a common virus that contributes to an estimated 630,000 new cancer cases annually worldwide (1). Cancer of the cervix represents over 80 percent of the cases caused by the virus. According to the CDC, other types of cancers have been attributed to HPV, such as 70 percent of oropharyngeal cancer, 90 percent of anal cancer, and 70 percent of vaginal and vulvar cancer (2). There are 100 different types of HPV, many of which do not cause cancer. However, researchers have identified 6 HPV types as definite human carcinogens (3).

Is there any way to help get rid of HPV infections? Read on to learn more about how HPV affects the body and why a supplement called AHCC may be able to help.

Do HPV Infections Go Away?

HPV often disappears from Pap test results within about two years, often without any treatment. While this scenario happens in the majority of cases, it does not always occur that way.

In some instances of HPV infections, the virus stays dormant and surfaces many years later. In these cases, the infections never really get resolved, and HPV ends up lingering for a long time. The body has a particularly hard time responding to the virus in people with weakened immune systems. When the infection persists, the potential for more serious complications increases, leading to the incidence of cervical cancer, genital warts, and other issues.

What’s the Most Effective Approach to Treat HPV?

Optimal immune function is essential to defend against pathogenic invaders like HPV. While there is no known cure for HPV infections, strengthening the immune system with natural substances such as AHCC has shown promising results.

AHCC is a cultured extract of various species of medicinal mushroom mycelia (roots). It has an immune-boosting effect that enables it to assist the body in eradicating the virus. This extract enhances immune function by increasing the number and activity of natural killer cells and other immune cells.

Over 30 human clinical trials looked at the effectiveness of AHCC in the treatment of many severe conditions, such as head and neck cancer, liver cancer, and HPV-positive cervical cancer. The results of these studies have been so impressive that some of the most prestigious institutions around the world have studied AHCC.

A pilot study at the University of Texas Health Science Center at Houston followed 10 HPV-positive women who took 3 grams of AHCC once daily for three months, and up to six months. At the end of the trial, 50% of the women tested negative for HPV (4). These are incredibly encouraging results considering that there is currently no cure for the condition.

What Dosage of AHCC Should I Take to Eradicate HPV?

Based on the best available scientific evidence, 3 grams of HPV cure AHCC. Daily AHCC appears to be an effective AHCC HPV dosage for the eradication of HPV. Treatment with this supplement makes the virus dormant in the body, so to achieve continuous suppression, it is important to continue taking the supplement indefinitely.
Editor’s pick:  Active Hexose Correlated Compound by HPD Rx This supplement is clinically tested and made from the highest quality ingredients.  

Sources

1. Worldwide burden of cancer attributable to HPV by site, country and HPV type: National Institutes of Health, 2017.
2. HPV-Associated Cancer Statistics: Centers for Disease Control and Prevention, 2018.
3. Global burden of human papillomavirus and related diseases: National Institutes of Health, 2012.
4. Mushroom extract, AHCC, helpful in treating HPV: ScienceDaily, 2014.

Discount on AHCC – Joy of soul and body

I’m halfway through my second can now, and although this drug should be taken longer, I’ll report back now because of the discount. The drug is expensive and 10% if you buy several jars can be a significant savings.

I drink at the maximum dose presented on the website of 750 mg per capsule (there are 250 mg and 500 mg). Take 2 capsules in the morning on an empty stomach with a glass of water.
AHCC is an abbreviation of the English words (Active Hemi-Cellulose Compound) (Active Hexose Correlation Complex).
Produced from medicinal mushrooms by a proprietary mushroom mycelium culturing process. clinical efficacy.

AHCC technology was developed by the Japanese company Amino UP Chemical Co. Ltd. (Sapporo) and Dr. Toshihiko Okamoto from the Faculty of Pharmacology, University of Tokyo in 1989. The process looks like this. A hybrid of shiitake, maitake and reishi is grown in a liquid nutrient medium based on brown rice. The shell of rice grains is rich in cellulose. Shiitake, maitake, and reishi mushrooms lack chlorophyll and, unlike plants, are not capable of photosynthesis. So they eat like animals. They release enzymes into the environment, digest the nutrients there, and absorb them. During this process, rice cellulose, a high molecular weight polysaccharide, is broken down by fungal enzymes (carbohydrases) into small fragments – oligosaccharides. After a certain period of cultivation, the mushroom material with fermentation products is centrifuged, concentrated and subjected to dry freezing. Then it is packaged in capsules. This information is googled, I am not a doctor and I do not understand this, who is interested there is a lot of information in all languages ​​..

My impressions after 1.5 months of taking 2 capsules per day (1500 mg).
I started taking this supplement during a sluggish flu, I can’t say that I was cured right away, it just took a long time, but I endured it on my feet.
In the reviews I read that many papillomavirus passes after taking AHCC. I don’t know for sure whether I have it or not, I didn’t do any tests, but there are a few small ones on my body, they haven’t gone anywhere, well, maybe they’ve become a little less ..
In general, I drink in a prophylactic dose before the autumn-winter season. From what I can note, this is a good mood, i.e. there are mental improvements and no fatigue, although I sleep very little. Usually during the day I want to sleep terribly, besides I am a hippotonist. Now in this regard I feel like a man, despite the difficult, busy period, perhaps the drug affects the pressure. I believe in the usefulness of this complex and taking advantage of the discount, I will buy more .. The price is unfortunately high .. (The capsules themselves are of a standard size, they are swallowed easily. The instructions do not say, but there is a general recommendation to drink mushroom complexes with 1-2 glasses of water in 30-40 minutes before meals

AHCC instructions for use

AHCC recommended doses.

1. Doses for disease prevention:

AHCC 1000-3000 mg or 2-6 capsules per day in three divided doses. Children for the purpose of prevention – 1 capsule 1 time per day.

2. Support in the treatment of cancer, prevention of side effects of anti-cancer therapy:

AHCC 3000-6000 mg or 6-12 capsules per day.

The Association for the Study of AHCC recommends that AHCC support the immune system in all cancers except blood disorders.

ANSS: indications

– Benign and malignant neoplasms.

– Immunodeficiency.

– Hepatitis B and C.

– Diabetes.

– Herpes.

– Skin viral diseases.

– Atopic dermatitis.

– Weakened immunity.

– Chronic fatigue syndrome.

– Urogenital infections.

The drug should not be taken in case of individual intolerance to at least one of the components, as well as in case of blood diseases.

AHCC is being investigated in the United States, China, Korea, Japan and Thailand. AHCC has been used as a supplement for patients with cancer, AIDS, hepatitis C, diabetes, hypertension, and autoimmune diseases. There are claims for its use in the treatment of wounds, stomach ulcers, gingivitis, fatigue syndrome, parasites and multiple sclerosis.
Backed by over 20 human clinical studies, AHCC is used in over 1,000 clinics worldwide. AHCC research has been conducted at some of the world’s most renowned research institutions, including highly regarded Ivy League universities. The uniqueness of the drug is that it changes both the innate and adaptive immune response.

My code is KFG537 gives a 5% discount on any order, thanks if you use it).

Tags: for health, for health-strengthening immunity, discounts/promotions, advise
first cheaper
by name

Japanese AHCC

The use of high molecular weight polysaccharides for the treatment of cancer was first developed by the Japanese company Amino UP Chemical Co. Ltd. A mixture based on shiitake, maetake and reishi mushrooms is a natural AHCC complex.

Revolutionary formula works with polysaccharides, amino acids and minerals. It is prescribed for pathologies of internal organs, oncological diseases.

AHCC preparation: composition and features

1. Shiitake. Components are used at increased risks of cancer and for the treatment of cancer patients. Mycelium is relevant for immunodeficiency syndrome, hepatitis. Penetrating into the cells, shiitake curb the progression of the disease, reducing the manifestation of symptoms.

2. Maetaki (dancing mushroom). Immunomodulating properties prevent the degeneration of benign formations. Also, the ANSS ingredient normalizes blood pressure, prevents the development of hypertension, and maintains blood sugar levels. By activating macrophages, they stimulate the reaction of cell defense.

3. Reishi. It is relevant for oncological pathologies of the esophagus, liver, pancreas, lungs, bone tissue and brain. It is used in medicine for the treatment of joints, respiratory problems.

Indications for the use of AHCC

According to the opinions of specialists and patients, AHCC is necessary as an additional support in diagnosing:

• malignant and benign neoplasms;

• immunodeficiency virus, immunocompromised;

• type 2 diabetes;

• liver diseases, including hepatitis B and C;

• skin diseases, herpes and other viral infections;

• irritability, chronic fatigue syndrome.

Properties Additive AHCC

The effectiveness of the drug has been proven by laboratory tests. The dose for prevention is 1000-300 mg of the active substance. When using a cancer support supplement, the dosage is increased to 3000-6000 mg. Benefits:

• Polysaccharides have a beneficial effect on the links of cellular immunity, activate T-helpers when the components are absorbed by macrophages;

• Stimulate the natural reproduction of T-helpers in the body;

• ANSS has a direct antitumor effect, inhibiting and reducing the growth of neoplasms that suppress the effective functioning of the immune system;

• Promotes the release of interferon-gamma, necessary for the activation of macrophages;

• Protects the liver from the negative effects of drugs, chemotherapy and radiotherapy;

• Performs the task of a powerful antioxidant during the rehabilitation period.